



**INTERNATIONAL JOURNAL OF
PHARMACEUTICAL SCIENCES**
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: <https://www.ijpsjournal.com>



Review Article

Dengue Fever Management: Pathophysiology, Therapeutic Challenges, Potential of *Carica Papaya* Leaf, and Advanced Drug Delivery Systems

Prakarsh Giri*, Dhananjay Rai

Institute of Pharmacy, Harish Chandra Post Graduate College, Bawan beegha, Varanasi.

ARTICLE INFO

Published: 22 Oct 2026

Keywords:

Dengue; *Carica papaya*;
Dengue virus;
Thrombocytopenia;
Phytoconstituents; Herbal
therapeutics; Drug delivery
systems; Microemulsion;
Bioavailability;
Phytopharmaceuticals

DOI:

10.5281/zenodo.23572759

ABSTRACT

Dengue is a major mosquito-borne viral disease with a broad clinical spectrum ranging from self-limiting febrile illness to severe dengue associated with plasma leakage, thrombocytopenia, hemorrhage, shock, and multi-organ dysfunction. Despite advances in diagnosis and supportive management, the lack of a widely effective specific antiviral therapy remains a major therapeutic challenge. Consequently, increasing attention has been directed toward medicinal plants and bioactive phytoconstituents as potential complementary therapeutic approaches. Among these, *Carica papaya* L. has attracted considerable interest because of its reported platelet-supportive, antioxidant, anti-inflammatory, immunomodulatory, and potential antiviral properties. However, variability in plant material, phytochemical composition, extraction procedures, dose, stability, and bioavailability limits the reproducibility and pharmaceutical translation of conventional *C. papaya* preparations. This review summarizes the current understanding of dengue virology, pathophysiology, clinical progression, diagnosis, therapeutic management, and major unmet therapeutic needs, with particular emphasis on the pharmacological potential and evidence supporting *C. papaya* leaf in dengue. The review further discusses the phytochemical basis, proposed molecular mechanisms, preclinical and clinical evidence, safety considerations, and limitations of conventional preparations. In addition, advanced drug-delivery systems, including liposomes, phytosomes, nanoemulsions, lipid nanoparticles, and microemulsions, are evaluated for their potential to improve the solubility, stability, bioavailability, and formulation consistency of herbal therapeutics. Particular emphasis is placed on microemulsion-based delivery as a rational strategy for improving the pharmaceutical performance of *C. papaya* leaf extract. Finally, current research gaps and future perspectives involving extract standardization, mechanistic validation, pharmacokinetic studies, formulation optimization, toxicological evaluation, and well-designed clinical trials are highlighted. Integrating standardized phytochemistry with advanced drug-delivery technologies may provide a promising pathway for the development of reproducible *C. papaya*-based

***Corresponding Author:** Prakarsh Giri

Address: Institute of Pharmacy, Harish Chandra Post Graduate College, Bawan beegha, Varanasi.

Email ✉: giriprakarsh@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.



therapeutic formulations for dengue management.

INTRODUCTION

Dengue is a mosquito-borne viral disease caused by dengue virus (DENV), an enveloped, positive-sense single-stranded RNA virus belonging to the *Flaviviridae* family. It represents a major global health problem, particularly in tropical and subtropical regions where competent *Aedes* mosquito vectors are widely distributed. The clinical spectrum ranges from an uncomplicated febrile illness to severe dengue characterized by plasma leakage, hemorrhage, shock, and organ dysfunction. The increasing geographical distribution of dengue is associated with urbanization, population mobility, climatic variability, and expansion of *Aedes* vector habitats.

Current dengue management is predominantly supportive because effective broadly applicable antiviral therapy remains an unmet need. Management therefore focuses on early diagnosis, adequate fluid therapy, monitoring of hematological parameters, and prevention of complications. This therapeutic limitation has stimulated interest in medicinal plants and

phytoconstituents with antiviral, antioxidant, anti-inflammatory, immunomodulatory, and platelet-supportive properties.

Among medicinal plants, *Carica papaya* L. has attracted considerable research interest because its leaves contain diverse bioactive constituents and have been investigated particularly for dengue-associated thrombocytopenia and inflammatory responses. However, variability in plant material, extraction procedures, phytochemical composition, dose, and bioavailability limits direct translation of conventional preparations into standardized pharmaceutical products.

Advanced drug-delivery systems may overcome some of these limitations by improving solubilization, stability, dispersion, bioavailability, and delivery of plant-derived bioactive constituents. Among these systems, microemulsions offer a promising approach because of their thermodynamic stability, nanoscale droplets, high solubilization capacity, and potential to improve the pharmaceutical performance of poorly soluble herbal constituents.

Table 1. Major therapeutic challenges in dengue and potential role of advanced delivery systems

Therapeutic challenge	Potential implication	Advanced delivery opportunity
Limited specific antiviral therapy	Dependence on supportive management	Improved delivery of bioactive compounds
Variable herbal composition	Inconsistent therapeutic response	Standardized pharmaceutical formulations
Poor solubility of phytoconstituents	Reduced bioavailability	Enhanced solubilization
Phytochemical instability	Loss of biological activity	Protection within delivery systems
Variable absorption	Unpredictable systemic exposure	Improved dispersion and absorption
Dose standardization	Difficulty in reproducibility	Controlled formulation design

2. Dengue Virus: Virology and Biological Characteristics

Dengue virus is a member of the genus *Flavivirus* within the family *Flaviviridae*. Four antigenically

distinct serotypes, DENV-1, DENV-2, DENV-3, and DENV-4, are responsible for human dengue infection. Infection with one serotype generally produces long-lasting immunity against that



serotype, whereas protection against other serotypes is incomplete and transient.

DENV possesses an approximately 11-kb positive-sense single-stranded RNA genome enclosed within an enveloped virion. The genome encodes three structural proteins—capsid (C), premembrane/membrane (prM/M), and envelope (E) and seven non-structural proteins, NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5. Structural proteins participate primarily in virion assembly and host-cell entry, whereas non-structural proteins regulate viral replication, polyprotein

processing, membrane rearrangement, and immune evasion.

Following transmission through the bite of an infected female *Aedes* mosquito, DENV initially infects susceptible cells and undergoes intracellular replication. Viral entry, genome translation, RNA replication, assembly, maturation, and release occur through coordinated interactions between viral proteins and host-cell machinery. The biological outcome of infection is influenced by viral serotype and genotype, host immunity, age, genetic factors, and previous exposure to DENV.




Figure 1. Structural organization and genome of dengue virus.

Table 2. Major dengue virus proteins and their functions

Protein	Type	Principal function
C	Structural	RNA encapsidation and nucleocapsid formation
prM/M	Structural	Virion assembly and maturation
E	Structural	Host-cell attachment, entry and membrane fusion
NS1	Non-structural	Replication-associated and host-interaction functions
NS2A	Non-structural	Viral replication and assembly
NS2B	Non-structural	Cofactor for NS3 protease
NS3	Non-structural	Protease and helicase activities
NS4A/NS4B	Non-structural	Replication-complex formation and immune modulation
NS5	Non-structural	RNA-dependent RNA polymerase and methyltransferase

3. Pathophysiology and Pathogenesis of Dengue

Dengue pathogenesis results from a complex interaction between viral replication and host immune responses. Following mosquito-mediated

inoculation, DENV infects susceptible cells and disseminates through the host. Viral replication activates innate immune mechanisms involving pattern-recognition receptors and induces production of interferons, cytokines, and



chemokines. These responses contribute to viral control but may also promote excessive inflammation.

Secondary infection with a different serotype represents an important risk factor for severe disease. Pre-existing non-neutralizing antibodies may facilitate viral uptake through Fc-receptor-bearing cells, a phenomenon known as antibody-dependent enhancement (ADE). Enhanced viral infection can increase immune activation and contribute to disease severity.

A major pathological feature of severe dengue is endothelial dysfunction with increased vascular permeability. Cytokines, viral components, NS1-associated mechanisms, complement activation,

and other inflammatory mediators can disrupt endothelial integrity, resulting in plasma leakage, hemoconcentration, pleural effusion, ascites, and potentially hypovolemic shock. Thrombocytopenia develops through multiple mechanisms, including reduced platelet production, increased destruction, immune-mediated mechanisms, and platelet activation/consumption.

Dysregulated inflammatory signaling, oxidative stress, endothelial injury, coagulation abnormalities, and immune activation collectively contribute to tissue injury. In severe cases, these processes may progress to hepatic, renal, neurological, cardiac, or gastrointestinal dysfunction and ultimately multi-organ failure.




Figure 3. Integrated pathophysiological mechanisms involved in dengue progression

Table 3. Major pathological mechanisms in dengue

Pathological mechanism	Major consequence
Viral replication	Systemic infection and cellular injury
Innate immune activation	Cytokine and interferon responses
Immune dysregulation	Excessive inflammatory response
ADE	Enhanced infection during certain secondary infections
Endothelial dysfunction	Increased vascular permeability
Plasma leakage	Hemoconcentration and hypovolemia
Platelet dysfunction/reduction	Thrombocytopenia and bleeding tendency

Coagulation abnormalities	Hemorrhagic manifestations
Oxidative stress	Cellular and tissue injury
Excessive inflammation	Organ damage and severe disease

4. Clinical Manifestations and Disease Progression

The clinical course of dengue typically develops after an incubation period of approximately 4–10 days following infection. The disease progresses through febrile, critical, and recovery phases, although the clinical presentation varies among patients.

The febrile phase is characterized by sudden high-grade fever, headache, retro-orbital pain, myalgia, arthralgia, nausea, vomiting, rash, and variable hematological abnormalities. Most patients recover without major complications; however, a subset progresses to the critical phase, which commonly occurs around the time of defervescence. During this phase, increased vascular permeability may cause plasma leakage, hemoconcentration, hypotension, bleeding, and shock.

The recovery phase begins when vascular permeability normalizes and leaked fluid is gradually reabsorbed. Excessive fluid administration during this phase may contribute to fluid overload. Clinically, dengue can also be classified according to the presence or absence of warning signs and severe disease. Warning signs include abdominal pain or tenderness, persistent vomiting, clinical fluid accumulation, mucosal bleeding, lethargy or restlessness, liver enlargement, and progressive hematological changes.

Severe dengue is characterized by severe plasma leakage leading to shock or respiratory distress, severe bleeding, or severe organ involvement. Hepatic injury, acute kidney injury, neurological manifestations, myocarditis or cardiac dysfunction, and gastrointestinal complications may occur in severe disease.

Table 4. Clinical phases and major manifestations of dengue

Phase	Major clinical features	Important concerns
Incubation	Usually asymptomatic	Viral replication
Febrile	High fever, headache, myalgia, rash, nausea	Dehydration and early hematological changes
Critical	Defervescence, plasma leakage, thrombocytopenia	Shock, bleeding, organ dysfunction
Recovery	Reabsorption of extravascular fluid, clinical improvement	Fluid overload if overhydrated
Severe dengue	Severe plasma leakage, major bleeding or organ involvement	Shock, multi-organ dysfunction

Organ-specific complications

- **Hepatic:** Elevated transaminases, hepatitis, hepatocellular injury and, rarely, acute liver failure.
- **Neurological:** Encephalopathy, encephalitis, seizures and other neurological manifestations.
- **Renal:** Acute kidney injury, particularly in severe systemic disease.



- **Cardiac:** Myocarditis, arrhythmias and myocardial dysfunction.
- **Gastrointestinal:** Abdominal pain, vomiting, gastrointestinal bleeding and hepatic-associated gastrointestinal disturbances.

5. Diagnosis and Biomarkers of Dengue

Dengue diagnosis requires integration of clinical findings, disease stage, epidemiological exposure, and laboratory investigations. Because early dengue may resemble other febrile illnesses, laboratory confirmation is important, particularly in regions with high dengue transmission.

5.1 Clinical Diagnosis

Dengue should be suspected in patients presenting with acute febrile illness accompanied by headache, retro-orbital pain, myalgia, arthralgia, nausea, vomiting, rash, or leukopenia, particularly in endemic settings. Warning signs and evidence of plasma leakage should be assessed to identify patients at risk of severe disease.

5.2 Complete Blood Count and Hematological Changes

Complete blood count commonly demonstrates leukopenia and thrombocytopenia. Progressive hematocrit elevation may indicate plasma leakage and is particularly important during the critical phase. Serial hematological monitoring is therefore more informative than a single measurement.

5.3 Platelet Count as a Clinical Parameter

Thrombocytopenia is a characteristic hematological abnormality of dengue and results from impaired platelet production, increased peripheral destruction, immune-mediated mechanisms, and platelet consumption. However,

platelet count alone does not reliably predict bleeding severity and should be interpreted with clinical findings and hematocrit changes.

5.4 NS1 Antigen Detection

Non-structural protein 1 (NS1) is detectable during the early phase of infection and can support diagnosis before the development of a significant antibody response. NS1 detection is particularly useful during the first days of illness.

5.5 RT-PCR and Molecular Diagnosis

Reverse transcription polymerase chain reaction (RT-PCR) enables detection of viral RNA and can provide serotype information during the early viremic phase. Molecular methods offer high analytical specificity but require appropriate laboratory infrastructure and technical expertise.

5.6 IgM and IgG Antibody Detection

Anti-DENV IgM generally becomes detectable after the initial days of infection and indicates recent infection, whereas IgG may persist for prolonged periods. The interpretation of IgM/IgG results should consider whether the infection is primary or secondary.

5.7 Rapid Diagnostic Tests

Rapid diagnostic tests combining NS1 antigen and/or antibody detection provide relatively accessible point-of-care testing. Their diagnostic performance varies with assay type, disease stage, serotype, and primary versus secondary infection.

5.8 Biochemical and Inflammatory Biomarkers

Elevated hepatic transaminases, altered renal parameters, and inflammatory mediators may accompany dengue. Biomarkers such as cytokines, chemokines, and endothelial injury markers have



been investigated for predicting disease severity, although their routine clinical application remains limited.

5.9 Differential Diagnosis

Dengue may clinically overlap with chikungunya, Zika virus infection, malaria, enteric fever, leptospirosis, influenza, COVID-19, and other acute febrile illnesses. Differential diagnosis is therefore essential, particularly in endemic regions with multiple circulating infections.

5.10 Limitations of Current Diagnostic Approaches

Diagnostic sensitivity varies according to the timing of specimen collection, assay characteristics, serotype, and immune status. No single test provides optimal sensitivity throughout the entire disease course; therefore, stage-appropriate diagnostic testing and clinical correlation are essential.

Table 5. Major diagnostic approaches for dengue

Diagnostic method	Principal target	Major application
CBC	Hematological changes	Monitoring disease progression
NS1 antigen	Viral NS1 protein	Early diagnosis
RT-PCR	Viral RNA	Early confirmation and serotyping
IgM	Anti-DENV antibody	Recent infection
IgG	Anti-DENV antibody	Previous/recent exposure and secondary infection
Rapid tests	NS1/antibodies	Point-of-care diagnosis
Biochemical markers	Organ/inflammatory changes	Assessment of severity

6. Current Therapeutic Management of Dengue

There is currently no universally established specific antiviral treatment that directly eliminates DENV in routine clinical practice; therefore, management primarily aims to maintain adequate circulation, prevent shock, recognize warning signs early, and manage complications.

6.1 General Principles of Dengue Management

Management depends on disease severity, clinical phase, warning signs, comorbidities, and laboratory findings. Early recognition of the transition from the febrile to critical phase is essential because rapid deterioration may occur around defervescence.

6.2 Supportive and Symptomatic Therapy

Supportive treatment includes adequate oral or intravenous fluid replacement, monitoring of vital

signs and urine output, nutritional support, and appropriate antipyretic therapy. Acetaminophen/paracetamol is generally preferred for fever and pain, whereas aspirin and non-steroidal anti-inflammatory drugs are avoided because of bleeding risk.

6.3 Fluid Management and Prevention of Shock

Careful fluid management is the cornerstone of severe dengue treatment. Isotonic crystalloids are commonly used according to clinical status, hematocrit, urine output, and evidence of plasma leakage. Both inadequate resuscitation and excessive fluid administration can cause serious complications.

6.4 Management of Fever and Pain

Fever and pain are generally managed with paracetamol and physical cooling measures when



appropriate. Drugs that increase bleeding risk should be avoided.

6.5 Management of Bleeding and Hemorrhagic Complications

Patients with clinically significant bleeding require assessment of hemodynamic status, hematological parameters, and coagulation abnormalities. Management is directed toward stabilization and treatment of the underlying cause rather than routine prophylactic transfusion.

6.6 Platelet Transfusion: Indications and Limitations

Routine prophylactic platelet transfusion based solely on a low platelet count is generally not recommended. Transfusion decisions should consider clinically significant bleeding, hemodynamic instability, invasive procedures, and the overall clinical condition.

6.7 Management of Severe Dengue

Severe dengue requires close monitoring and timely management of shock, severe bleeding, respiratory compromise, and organ dysfunction. Fluid therapy should be carefully titrated to avoid both persistent hypoperfusion and fluid overload.

6.8 Management of Organ Complications

Hepatic, renal, neurological, and cardiac complications require organ-specific supportive

management. Patients with severe manifestations may require intensive-care monitoring.

6.9 Antiviral Drug Development for Dengue

Multiple antiviral strategies have been investigated, including inhibitors targeting viral entry, NS2B/NS3 protease, NS4B, NS5 polymerase, and host–virus interactions. However, achieving broad activity against all serotypes while maintaining adequate safety and clinical efficacy remains challenging.

6.10 Investigational and Emerging Therapeutic Approaches

Current research includes direct-acting antivirals, host-targeted therapies, monoclonal antibodies, immunomodulatory approaches, and repurposed drugs. Most remain under experimental or clinical investigation.

6.11 Limitations of Conventional Dengue Therapy

The major limitation is the predominance of supportive rather than disease-modifying treatment. In addition, rapid disease progression, absence of a broadly effective antiviral, and limited therapeutic options for severe disease highlight the need for novel pharmacological strategies.

Table 6. Current and emerging therapeutic approaches

Approach	Therapeutic objective	Current status
Fluid therapy	Prevent/treat hypovolemic shock	Established
Paracetamol	Fever and pain control	Established
Blood products	Management of significant bleeding	Selective use
Direct-acting antivirals	Inhibit viral replication	Investigational
Host-targeted therapy	Modulate host factors	Investigational
Monoclonal antibodies	Neutralize virus	Investigational
Immunomodulatory therapy	Control excessive inflammation	Investigational
Herbal therapeutics	Multitarget pharmacological effects	Requires further validation



7. Therapeutic Challenges and Unmet Needs in Dengue

Despite improvements in diagnosis and supportive care, important therapeutic gaps remain. The absence of a broadly effective specific antiviral therapy represents the principal unmet need. DENV exists as four antigenically distinct serotypes with substantial genetic diversity, complicating the development of universally effective therapeutics.

Secondary infection with a heterologous serotype can produce complex immune responses, including ADE, which may increase the risk of severe disease. Furthermore, dengue can progress rapidly from an apparently uncomplicated febrile illness to plasma leakage, shock, bleeding, and organ dysfunction.

Thrombocytopenia remains another important clinical challenge, although platelet count alone is not an adequate indicator of bleeding risk. The absence of standardized pharmacological interventions specifically targeting platelet recovery, endothelial dysfunction, and viral replication further limits treatment options.

Safety is also critical because patients may already have hepatic, renal, or hematological abnormalities. Consequently, novel therapeutic candidates require rigorous evaluation of efficacy, toxicity, pharmacokinetics, standardization, and interactions with conventional supportive treatments.

Advanced drug-delivery systems may provide an opportunity to improve the pharmaceutical performance of promising bioactive compounds by enhancing solubility, stability, bioavailability, and formulation reproducibility.

Table 7. Major unmet therapeutic needs in dengue

Challenge	Research requirement
Lack of effective broad-spectrum antiviral	Development of multitarget antivirals
Serotype diversity	Broad-spectrum therapeutic strategies
ADE	Safer immune-modulating approaches
Plasma leakage	Endothelial-protective strategies
Thrombocytopenia	Mechanism-based platelet-supportive therapies
Rapid disease progression	Early disease-modifying interventions
Herbal variability	Standardized extracts and formulations
Poor bioavailability	Advanced drug-delivery systems
Limited clinical evidence	Well-designed randomized trials

8. Medicinal Plants and Phytoconstituents in Dengue Management

Medicinal plants represent a potential source of structurally diverse bioactive compounds that may act through multiple pharmacological pathways relevant to dengue. Unlike single-target synthetic agents, plant-derived preparations may provide combined antioxidant, anti-inflammatory, immunomodulatory, antiviral, and hematological

effects. However, these potential benefits should be distinguished from clinically established efficacy.

Several medicinal plants have been investigated experimentally for dengue-associated effects, including *Carica papaya*, *Azadirachta indica*, *Andrographis paniculata*, *Tinospora cordifolia*, *Ocimum* species, and other traditionally used plants. Their reported activities are largely



associated with flavonoids, phenolic compounds, terpenoids, alkaloids, polysaccharides, and other secondary metabolites.

8.1–8.2 Rationale and Traditional Use

Traditional medicinal systems have used numerous plants for fever, inflammation, infections, and hematological disorders. Their relevance to dengue has encouraged scientific investigation of extracts and isolated phytoconstituents.

8.3–8.8 Phytochemical and Pharmacological Potential

Phytoconstituents investigated in dengue-related research include flavonoids, phenolic acids, terpenoids, alkaloids, and other antioxidant molecules. Proposed activities include inhibition of viral replication, attenuation of inflammatory signaling, reduction of oxidative stress, immunomodulation, and potential effects on platelet production or survival.

8.9–8.11 Evidence From Experimental and Clinical Studies

In-vitro studies provide evidence for antiviral, antioxidant, or anti-inflammatory activity of selected plant extracts and compounds. Animal studies further investigate pharmacological mechanisms and safety. Clinical studies, particularly involving *C. papaya* leaf preparations, have reported potential effects on platelet recovery; however, differences in preparation, dose, study design, and outcome measures limit definitive conclusions.

8.12 Limitations of Herbal Approaches

Major limitations include variability in phytochemical composition, lack of extract standardization, inconsistent dosing, uncertain bioavailability, differences in extraction methods, limited pharmacokinetic information, and insufficient high-quality clinical evidence. Therefore, pharmaceutical formulation and standardization are essential for translating promising herbal evidence into reproducible therapeutic products.

Table 8. Potential pharmacological activities of medicinal plants in dengue

Pharmacological activity	Potential relevance to dengue
Antiviral	Suppression of viral replication or entry
Anti-inflammatory	Reduction of excessive inflammatory signaling
Antioxidant	Attenuation of oxidative stress
Immunomodulatory	Regulation of host immune responses
Platelet-supportive	Potential improvement in thrombocytopenia
Endothelial protective	Potential reduction of vascular dysfunction
Multitarget activity	Simultaneous modulation of multiple disease pathways

9. *Carica papaya* L.: Botanical and Phytochemical Profile

Carica papaya L. belongs to the family Caricaceae and is a fast-growing tropical plant cultivated extensively in Asia, Africa, and Central and South America. The plant is characterized by a soft,

hollow stem, large palmately lobed leaves, and fruit containing numerous seeds. Leaves are of particular pharmacological interest because they contain a diverse range of secondary metabolites and nutritional constituents.



Traditionally, different parts of *C. papaya* have been used for digestive disorders, fever, inflammatory conditions, wound management, and other ailments. The leaves have subsequently attracted scientific interest because of their reported antioxidant, anti-inflammatory, immunomodulatory, antimicrobial, and hematological activities.

The phytochemical composition of *C. papaya* leaves is complex and can vary according to cultivar, geographical origin, maturity, environmental conditions, and extraction method. Major reported constituents include flavonoids, phenolic compounds, alkaloids, carotenoids, vitamins, minerals, enzymes, and other bioactive molecules.

9.1 Botanical Classification

Taxonomic rank	Classification
Kingdom	Plantae
Family	Caricaceae
Genus	<i>Carica</i>
Species	<i>Carica papaya</i> L.

9.2–9.4 Morphology, Distribution and Traditional Use

C. papaya is a perennial herbaceous plant widely cultivated in tropical and subtropical climates. Its leaves are large, palmately divided, and arranged near the upper portion of the stem. The plant grows efficiently under warm conditions and is extensively cultivated for its edible fruit. Leaves have traditionally been used in various herbal preparations, particularly for fever, digestive disorders, inflammatory conditions, and hematological complaints.

9.5–9.12 Phytochemical Constituents

The pharmacological potential of *C. papaya* leaves is associated with multiple classes of phytoconstituents. Flavonoids and phenolic compounds contribute substantially to antioxidant and anti-inflammatory activity, whereas alkaloids and other specialized metabolites may contribute to additional biological effects. Carotenoids, vitamins, minerals, enzymes, and proteins further contribute to the overall biochemical profile.

Table 9. Major phytochemical classes reported in *Carica papaya* leaves

Phytochemical class	Representative constituents/examples	Potential pharmacological relevance
Flavonoids	Quercetin and related flavonoids	Antioxidant, anti-inflammatory
Phenolics	Phenolic acids and related compounds	Antioxidant activity
Alkaloids	Carpaine and related alkaloids	Potential pharmacological effects
Carotenoids	β -Carotene and related pigments	Antioxidant activity
Vitamins	Vitamins A, C and other micronutrients	Antioxidant and nutritional effects
Minerals	Calcium, potassium, magnesium and others	Physiological functions
Enzymes/proteins	Papain-related and other proteins	Biological and enzymatic activities
Other metabolites	Terpenoids and other secondary metabolites	Diverse pharmacological activities

10. Therapeutic Potential of *Carica papaya* Leaf in Dengue

The therapeutic interest in *C. papaya* leaves in dengue is primarily associated with their reported effects on thrombocytopenia, inflammation, oxidative stress, and immune responses.

Importantly, the available evidence should be interpreted as promising but not conclusive, and *C. papaya* should not be considered a replacement for established supportive management.

10.1 Historical and Traditional Use



The use of *C. papaya* leaf preparations during dengue outbreaks has been reported particularly in South and Southeast Asia. Its popularity has stimulated experimental and clinical investigations into its potential effects on platelet recovery and disease-associated inflammatory responses.

10.2 Effects on Platelet Count

Several clinical and experimental studies have reported increased platelet counts following administration of *C. papaya* leaf preparations. Proposed explanations include enhanced platelet production, reduced platelet destruction, and modulation of hematopoietic pathways. However, differences in extract preparation, dosage, patient population, and study design limit direct comparison among studies.

10.3 Platelet Production and Megakaryopoiesis

Experimental evidence suggests that constituents of *C. papaya* may influence pathways associated with megakaryocyte maturation and platelet production. This potential effect is particularly relevant because thrombocytopenia is a prominent hematological abnormality in dengue.

10.4 Antiviral Potential

Certain phytoconstituents of *C. papaya* have demonstrated antiviral activity in experimental systems. Possible mechanisms include interference with viral entry, replication, or virus–host interactions. However, direct anti-DENV activity and its clinical relevance require further validation.

10.5 Anti-Inflammatory Activity

Flavonoids, phenolic compounds, and other constituents may attenuate inflammatory signaling by modulating mediators associated with

excessive immune activation. Such activity could theoretically reduce inflammation-associated tissue injury.

10.6 Antioxidant Activity

Oxidative stress contributes to cellular injury during systemic viral infection. The antioxidant constituents of *C. papaya* may scavenge reactive oxygen species and enhance endogenous antioxidant defense mechanisms.

10.7 Immunomodulatory Effects

C. papaya leaf constituents may influence innate and adaptive immune responses. However, the precise immunological effects in dengue remain incompletely characterized and require mechanistic investigation.

10.8 Potential Protection Against Vascular Dysfunction

Because endothelial dysfunction and increased vascular permeability contribute to severe dengue, the antioxidant and anti-inflammatory properties of *C. papaya* may have potential endothelial-protective relevance. Direct evidence for prevention of dengue-associated plasma leakage, however, remains limited.

10.9 Potential Effects on Dengue-Associated Complications

Through combined hematological, antioxidant, anti-inflammatory, and immunomodulatory activities, *C. papaya* may have potential to influence selected manifestations associated with dengue. Nevertheless, evidence for reduction in severe complications, hospitalization, or mortality remains insufficient for definitive therapeutic conclusions.

10.10 Proposed Molecular Mechanisms



The overall therapeutic hypothesis involves simultaneous modulation of platelet-associated pathways, inflammatory signaling, oxidative stress, immune responses, and potentially viral replication.

Table 10. Potential therapeutic actions of *Carica papaya* leaf in dengue

Activity	Proposed relevance
Platelet-supportive	Potential enhancement of platelet recovery
Anti-inflammatory	Modulation of excessive inflammatory responses
Antioxidant	Reduction of oxidative stress
Immunomodulatory	Regulation of host immune responses
Antiviral	Potential interference with viral processes
Endothelial-protective	Potential reduction of vascular injury
Multitarget action	Simultaneous modulation of disease-associated pathways

11. Evidence-Based Evaluation of *Carica papaya* in Dengue

The evidence supporting *C. papaya* in dengue comprises in-vitro, animal, preclinical, and clinical investigations, with platelet recovery being the most frequently investigated outcome. Experimental studies provide a biological rationale for its use, whereas clinical studies have produced encouraging but heterogeneous results.

11.1–11.3 In-Vitro, In-Vivo and Preclinical Evidence

In-vitro investigations have explored antioxidant, anti-inflammatory, antiviral, and cellular effects of *C. papaya* extracts and constituents. Animal studies have additionally investigated hematological responses, platelet-related effects, and potential mechanisms. Collectively, these findings provide pharmacological support but cannot independently establish clinical efficacy.

11.4–11.5 Clinical Studies and Randomized Trials

Clinical investigations have reported potential increases in platelet counts and improvements in selected hematological parameters following *C. papaya* leaf administration. Some randomized studies have reported favorable platelet-related

outcomes; however, differences in extract standardization, preparation, dosage, treatment duration, sample size, and concomitant supportive therapy complicate interpretation.

11.6 Systematic Reviews and Meta-Analyses

Systematic reviews and meta-analyses generally suggest a possible platelet-enhancing effect, but heterogeneity and methodological limitations reduce confidence in the evidence. Importantly, improvement in platelet count does not necessarily establish reduction in severe dengue, mortality, or other clinically meaningful outcomes.

11.7 Safety and Toxicological Evidence

Available studies generally suggest acceptable short-term tolerability of investigated preparations, but safety depends on dose, extraction method, preparation quality, and patient characteristics. Comprehensive toxicological and long-term safety data remain limited.

11.8 Dose and Administration Considerations

No universally standardized therapeutic dose of *C. papaya* leaf extract has been established for dengue. Variability in extract concentration and phytochemical composition makes direct dose comparison difficult.



11.9 Limitations of Existing Clinical Evidence

Major limitations include small sample sizes, heterogeneous preparations, inadequate standardization, variable endpoints, differences in disease severity, and limited pharmacokinetic information.

11.10 Research Gaps

Future studies should prioritize chemically standardized extracts, validated biomarkers, dose optimization, pharmacokinetic characterization, mechanistic studies, and adequately powered randomized controlled trials.

12. Mechanistic Basis of *Carica papaya* Activity in Dengue

The potential activity of *C. papaya* in dengue is likely multifactorial rather than dependent on a single pharmacological target. Its phytochemical constituents may interact with pathways involved in thrombopoiesis, inflammation, oxidative stress, immune regulation, endothelial integrity, and viral–host interactions.

12.1 Modulation of Platelet Production

One of the principal proposed mechanisms is enhancement of platelet production through modulation of megakaryopoietic pathways. This mechanism may contribute to the platelet recovery observed in some experimental and clinical studies.

12.2–12.3 Regulation of Inflammatory Mediators and Cytokines

Flavonoids and phenolic compounds may modulate inflammatory signaling pathways and cytokine production. Regulation of mediators such as TNF- α , IL-6, and other inflammatory molecules

could potentially reduce excessive systemic inflammation.

12.4 Antioxidant Mechanisms

Polyphenolic constituents can neutralize reactive oxygen species and may support endogenous antioxidant systems. Reduction of oxidative stress may limit cellular injury and inflammatory amplification.

12.5 Modulation of Viral Replication

Selected phytoconstituents may interact with viral proteins or host factors involved in DENV entry and replication. Computational and experimental studies have suggested possible interactions with viral targets, although these mechanisms require experimental confirmation.

12.6 Endothelial Protection

By reducing oxidative and inflammatory stress, *C. papaya* constituents may theoretically help preserve endothelial integrity. This mechanism is particularly relevant to the vascular permeability characteristic of severe dengue.

12.7 Immunomodulatory Mechanisms

The extract may modulate immune-cell activity and inflammatory signaling, potentially contributing to a more balanced host response. The precise direction and magnitude of these effects in dengue remain to be established.

12.8 Potential Molecular Targets and Signaling Pathways

Potentially relevant pathways include NF- κ B-associated inflammatory signaling, oxidative-stress pathways, cytokine signaling, platelet/megakaryocyte regulatory pathways, and viral replication-associated targets. These



mechanisms should be validated experimentally rather than inferred solely from computational studies.

platelet-supportive, antioxidant, anti-inflammatory, immunomodulatory, endothelial-protective, and potential antiviral effects.

12.9 Integrated Mechanistic Model

Overall, the proposed mechanism can be conceptualized as a coordinated interaction among

13. Limitations of Conventional *Carica papaya* Preparations

Table 13. Major limitations of conventional *Carica papaya* preparations

Limitation	Pharmaceutical consequence
Plant-material variability	Variation in phytochemical profile
Phytochemical variability	Inconsistent biological activity
Extraction-dependent composition	Variable extract quality
Poor standardization	Difficult dose comparison
Poor solubility	Limited dissolution and absorption
Chemical instability	Loss of active constituents
Dose variability	Reduced reproducibility
Low/variable bioavailability	Reduced therapeutic exposure
Batch-to-batch variation	Inconsistent product performance
Lack of optimized dosage form	Limited clinical translation

14. Advanced Drug Delivery Systems for Herbal Therapeutics

Table 14. Comparison of advanced drug-delivery systems

Delivery system	Major advantage	Important limitation
Liposomes	Versatile drug incorporation	Physical/chemical instability
Niosomes	Good vesicular stability	Surfactant-related limitations
Phytosomes	Improved phytoconstituent absorption	Limited applicability to all constituents
Nanoemulsions	Enhanced solubilization and dispersion	Physical stability considerations
Microemulsions	Thermodynamic stability and high solubilization	High surfactant requirement
SLNs	Protection and controlled release	Drug-loading limitations
NLCs	Higher loading capacity than SLNs	Formulation complexity
Polymeric nanoparticles	Controlled release and targeting potential	Polymer-related considerations
Transferosomes	Enhanced membrane transport	Vesicle stability challenges

15. Microemulsion-Based Drug Delivery for Herbal Extracts

Microemulsions are thermodynamically stable, isotropic, optically transparent or translucent dispersions consisting of oil, water, surfactant, and usually a co-surfactant. They generally possess nanoscale dispersed domains and can improve the incorporation and solubilization of compounds with limited aqueous solubility.

15.1 Definition and Basic Principles

Microemulsion formation occurs when appropriate proportions of oil, aqueous phase, surfactant, and co-surfactant reduce interfacial tension and facilitate spontaneous formation of a stable dispersed system.

15.2–15.6 Components of Microemulsion



The oil phase provides a lipophilic environment for poorly water-soluble constituents. Surfactants reduce interfacial tension and stabilize the oil–water interface, whereas co-surfactants improve interfacial flexibility and facilitate microemulsion formation. Water constitutes the aqueous phase and influences the final microstructure and physicochemical characteristics.

15.7 Mechanism of Microemulsion Formation

The surfactant and co-surfactant accumulate at the oil–water interface, reducing interfacial free energy and promoting formation of small dispersed domains. The resulting system depends strongly on the composition and ratio of the formulation components.

15.8 Pseudoternary Phase Diagrams

Pseudoternary phase diagrams are commonly employed to identify the microemulsion region and optimize the relative proportions of oil, Smix, and aqueous phase. Different surfactant-to-co-surfactant ratios can produce different phase boundaries and formulation domains.

15.9 Thermodynamic Stability

Unlike kinetically stable emulsions, microemulsions are thermodynamically stable systems under appropriate compositional conditions. Their stability is associated with favorable interfacial characteristics and low interfacial free energy.

15.10 Solubilization and Bioavailability Enhancement

Microemulsions can improve the apparent solubility and dispersion of poorly water-soluble phytoconstituents. The large interfacial area generated by small droplets may facilitate dissolution and potentially improve absorption.

15.11 Advantages

Major advantages include high solubilization capacity, improved dispersion, thermodynamic stability, ease of preparation, nanoscale droplets, and potential enhancement of bioavailability.

15.12 Limitations

Important limitations include the relatively high concentration of surfactants/co-surfactants that may be required, potential irritation or toxicity depending on the excipients and route of administration, limited drug-loading capacity for some compounds, and the need for careful optimization of formulation composition.

16. Potential of *Carica papaya* Leaf-Loaded Microemulsion for Dengue Management

The formulation of *C. papaya* leaf extract as a microemulsion represents a rational pharmaceutical strategy to address some limitations associated with conventional herbal preparations. The primary objective is not to alter the inherent pharmacological activity of the extract but to improve its physicochemical and biopharmaceutical performance.

16.1 Rationale for Microemulsion-Based Delivery

A microemulsion may provide a suitable environment for incorporating phytoconstituents with different polarity and solubility characteristics. Improved dispersion and solubilization may enhance formulation uniformity and potentially improve bioavailability.

16.2 Selection of Pharmaceutical Excipients

Selection of the oil, surfactant, co-surfactant, and aqueous phase should be based on extract



solubilization capacity, formulation compatibility, safety, microemulsion-region size, stability, and intended route of administration.

16.3 Enhancement of Extract Solubilization

Incorporation into the internal phase or interfacial region can improve the apparent solubility and dispersion of poorly water-soluble phytoconstituents, potentially providing more uniform delivery.

16.4 Improvement in Physical Stability

An appropriately optimized microemulsion can minimize problems associated with sedimentation, phase separation, and poor dispersion. However, stability must be experimentally established under defined storage conditions.

16.5 Potential Enhancement of Bioavailability

The nanoscale dispersed domains and large interfacial area may facilitate dissolution and interaction with biological membranes, potentially improving absorption of selected phytoconstituents.

16.6 Protection of Bioactive Phytoconstituents

The formulation environment may provide some protection against degradation of susceptible constituents caused by environmental or physicochemical factors. The degree of protection depends on the individual phytoconstituent and formulation composition.

16.7 Potential Improvement in Therapeutic Consistency

A standardized extract incorporated into a reproducible formulation may reduce some variability associated with conventional administration. However, formulation

standardization does not eliminate the inherent variability of the botanical starting material.

16.8 Important Formulation and Characterization Parameters

Evaluation should include droplet size, polydispersity index (PDI), zeta potential, pH, viscosity, conductivity, refractive index, extract/drug content, physical appearance, phase behavior, and stability. Together, these parameters provide information about formulation quality, dispersion characteristics, physical stability, and reproducibility.

16.9 Translational Potential and Challenges

A *C. papaya* leaf extract-loaded microemulsion could potentially provide a more standardized and pharmaceutically acceptable delivery platform than conventional extract preparations. However, translation requires extract standardization, identification/quantification of marker compounds, formulation reproducibility, comprehensive stability testing, pharmacokinetic studies, toxicity evaluation, and appropriately designed clinical studies.

17. Comparative Evaluation of Conventional and Advanced *Carica papaya* Delivery

Conventional *C. papaya* leaf preparations provide a simple means of administering plant-derived bioactive constituents but are associated with variability in solubility, stability, dose uniformity, and bioavailability. Advanced delivery systems can potentially overcome several of these limitations through controlled formulation design, improved solubilization, protection of labile constituents, and enhanced physicochemical consistency. However, these advantages remain formulation-dependent and require experimental and clinical validation.



Table 17. Comparison of conventional and advanced *Carica papaya* delivery systems

Parameter	Conventional Extract	Advanced Delivery System
Solubility	Variable	Potentially improved
Stability	Limited	Improved potential
Dose uniformity	Challenging	Better control
Bioavailability	Variable	Potential enhancement
Phytoconstituent protection	Limited	Better protection
Formulation reproducibility	Variable	Higher potential
Pharmaceutical acceptability	Limited	Improved
Physicochemical characterization	Relatively limited	Comprehensive
Quality control	Extract-dependent	Formulation- and extract-dependent

18. Regulatory, Safety and Translational Considerations

The development of *C. papaya*-based pharmaceutical products requires careful consideration of safety, standardization, quality control, and regulatory compliance. Although several studies have reported favorable short-term tolerability, the safety profile of a botanical preparation depends on plant source, extraction method, phytochemical composition, dose, duration, and patient characteristics.

18.1–18.3 Safety, Toxicology and Herb–Drug Interactions

Comprehensive toxicological evaluation is required before clinical translation. Potential herb–drug interactions should also be considered because dengue patients may receive multiple supportive medications and may have hepatic, renal, or hematological abnormalities.

18.4–18.6 Standardization, Quality Control and Reproducibility

Standardization should include authentication of plant material, controlled extraction, physicochemical characterization, identification or quantification of suitable marker compounds, and assessment of contaminants. Batch-to-batch consistency is essential for reproducible pharmacological activity.

18.7–18.8 Regulatory and Translational Challenges

Herbal formulations must satisfy appropriate quality, safety, efficacy, and manufacturing requirements. Translation from experimental studies to clinical application requires reproducible formulations, validated analytical methods, pharmacokinetic and toxicological data, and well-designed clinical trials.

19. Current Research Gaps

Table 18. Major research gaps and required research directions

Research gap	Required direction
Phytochemical variability	Standardized chemical fingerprinting
Unclear active constituents	Marker-compound identification
Limited mechanistic evidence	Molecular and cellular studies
Limited pharmacokinetic data	ADME and bioavailability studies
Dose uncertainty	Dose-response investigations
Limited toxicity data	Acute, subacute and chronic evaluation
Clinical heterogeneity	Well-designed randomized trials
Limited delivery-system studies	Formulation and characterization studies



Poor reproducibility	Standardized manufacturing and QC
Translational uncertainty	Integrated preclinical–clinical development

20. Future Perspectives

Future research should focus on transforming *C. papaya* from a traditionally used botanical preparation into a standardized, scientifically characterized and pharmaceutically reproducible therapeutic candidate. Advanced analytical techniques such as chromatographic and spectrometric fingerprinting can help establish chemical consistency and identify pharmacologically relevant markers.

Mechanistic investigations should integrate phytochemical profiling with molecular biology, cellular assays, computational approaches, and validated disease models. Pharmacokinetic and biodistribution studies are particularly important for determining whether potentially active constituents achieve therapeutically relevant exposure.

Advanced delivery platforms, including microemulsions, nanoemulsions, lipid nanoparticles, phytosomes, and other nanocarriers, may improve the pharmaceutical performance of standardized extracts. Among these, microemulsion-based delivery warrants further investigation for improving solubilization, dispersion, stability, and potentially bioavailability.

Ultimately, translation will require appropriately designed preclinical studies followed by adequately powered randomized clinical trials evaluating clinically meaningful outcomes rather than platelet count alone.

CONCLUSION

Dengue remains a significant global health challenge, with severe disease associated with plasma leakage, thrombocytopenia, inflammation, vascular dysfunction, and organ involvement. Current management is predominantly supportive, highlighting the need for safe and effective disease-modifying therapeutic approaches.

Carica papaya L. leaf has emerged as a promising botanical candidate because of its reported platelet-supportive, antioxidant, anti-inflammatory, immunomodulatory, and potential antiviral activities. However, variability in plant material, phytochemical composition, extraction procedures, dose, bioavailability, and clinical evidence limits definitive therapeutic translation.

Advanced drug-delivery systems offer a rational strategy for addressing several pharmaceutical limitations of conventional herbal preparations. In particular, microemulsion-based delivery may improve solubilization, dispersion, physicochemical stability, and formulation consistency of *C. papaya* leaf extract. Nevertheless, these potential advantages require systematic validation through standardized formulation studies, pharmacokinetic and toxicological investigations, and well-designed clinical trials.

REFERENCES

1. World Health Organization. Dengue: global situation, surveillance and progress – 2024 update. Wkly Epidemiol Rec. 2025;100(52):665-678.
2. World Health Organization. WHO guidelines for clinical management of arboviral diseases:



- dengue, chikungunya, Zika and yellow fever. Geneva: World Health Organization; 2025.
3. Paz-Bailey G, Adams LE, Deen J, Anderson KB, Katzelnick LC. Dengue. *Lancet*. 2024;403(10427):667-682. doi:10.1016/S0140-6736(23)02576-X.
4. Kalimuddin S, Chia PY, Low JG, Ooi EE. Dengue and severe dengue. *Clin Microbiol Rev*. 2025;38(4):e00244-24. doi:10.1128/cmr.00244-24.
5. Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, Gubler DJ, et al. Dengue: a continuing global threat. *Nat Rev Microbiol*. 2010;8(12 Suppl):S7-S16. doi:10.1038/nrmicro2460.
6. Rothman AL. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. *Nat Rev Immunol*. 2011;11(8):532-543. doi:10.1038/nri3014.
7. Martina BE, Koraka P, Osterhaus ADME. Dengue virus pathogenesis: an integrated view. *Clin Microbiol Rev*. 2009;22(4):564-581. doi:10.1128/CMR.00035-09.
8. See KC. Dengue-associated hemophagocytic lymphohistiocytosis: a narrative review of its identification and treatment. *Pathogens*. 2024;13(4):332. doi:10.3390/pathogens13040332.
9. Evaluating the performance of common reference laboratory tests for acute dengue diagnosis: a systematic review and meta-analysis of RT-PCR, NS1 ELISA, and IgM ELISA. [PubMed-indexed systematic review]. 2025.
10. Niranjana R, Saxena N, Das A. Dengue control, if not by vaccination and vector strategies, then possibly by therapeutics. *Lancet Infect Dis*. 2024;24(3):e144. doi:10.1016/S1473-3099(23)00782-X.
11. Ooi EE, Chan YF. Is a therapeutic dengue monoclonal antibody on the way? *Lancet Infect Dis*. 2024;24(6):567-568. doi:10.1016/S1473-3099(24)00083-5.
12. Medigeshi GR, Islam F, Lodha R. Quadrivalent dengue-virus vaccines: challenges and opportunities for India. *Lancet Infect Dis*. 2024;24(5):e270-e271. doi:10.1016/S1473-3099(24)00137-3.
13. Sharma A, et al. Carica papaya L. leaves: deciphering its antioxidant bioactives, biological activities, innovative products, and safety aspects. [Review]. 2022.
14. Akanda MKM, Hasan AHMN, Mehjabin S, Parvez GMM, Yasmin S, Akhtar MS, et al. Carica papaya in health and disease: a review of its bioactive compounds for treating various disease conditions, including anti-inflammatory and anti-arthritic activities. *Inflammopharmacology*. 2025;33(6):3051-3084. doi:10.1007/s10787-025-01780-4.
15. Choudhary R, Kaushik R, Akhtar A, Manna S, Sharma J, Bains A. Nutritional, phytochemical, and antimicrobial properties of Carica papaya leaves: implications for health benefits and food applications. *Foods*. 2025;14(2):154. doi:10.3390/foods14020154.
16. Development of quality standard and phytochemical analysis of Carica papaya Linn leaves. [Phytochemical standardization study]. 2018.
17. Rajapakse S, de Silva NL, Weeratunga P, Rodrigo C, Sigera C, Fernando SD. Carica papaya extract in dengue: a systematic review and meta-analysis. *BMC Complement Altern Med*. 2019;19(1):265. doi:10.1186/s12906-019-2678-2.
18. Subenthiran S, Choon TC, Cheong KC, Thayan R, Teck MB, Muniandy PK, et al. Carica papaya leaf juice significantly increases platelet count in patients with dengue fever and dengue haemorrhagic fever. *Evid Based Complement Alternat Med*. 2013;2013:616737. (Classic clinical evidence.)
19. Gadhwal AK, Ankit BS, Chahar C, Tania P, Sirohi P, Agrawal RP. Effect of Carica papaya leaf extract capsule on platelet count in patients of dengue fever with thrombocytopenia. *J Assoc Physicians India*. 2016;64(6):22-26.
20. Kasture PN, Nagabhushan KH, Kumar A. A multi-centric, double-blind, placebo-controlled, randomized, prospective study to evaluate the efficacy and safety of Carica papaya leaf extract, as empirical therapy for thrombocytopenia associated with dengue



- fever. *J Assoc Physicians India*. 2016;64(6):15-20.
21. Sathyapalan DT, Padinjakara RN, Moni M, et al. Efficacy & safety of *Carica papaya* leaf extract (CPLE) in severe thrombocytopenia ($\leq 30,000/\mu\text{L}$) in adult dengue: results of a pilot study. *PLoS One*. 2020;15(2):e0228699.
22. Teh BP, et al. *Carica papaya* leaf juice for dengue: a scoping review. *Nutrients*. 2022;14.
23. Lim XY, Chan JSW, Japri N, Lee JC, Tan TYC. *Carica papaya* L. leaf: a systematic scoping review on biological safety and herb-drug interactions. *Evid Based Complement Alternat Med*. 2021;2021:5511221. doi:10.1155/2021/5511221.
24. A review of potentials of *Carica papaya* leaves in dengue viral infection: insights of clinical and preclinical studies. *Drug Res (Stuttg)*. 2025. doi:10.1055/a-2509-8644.
25. Prospects of *Carica papaya* in the treatment of human viral infections: a comprehensive and systematic review. [Systematic review]. 2025.
26. Potentials of medicinal plants for the treatment of dengue fever and severe acute respiratory syndrome-coronavirus. [Review]. 2021.
27. Evolving herbal formulations in management of dengue fever. [Review]. 2017.
28. Date AA, Desai N, Dixit R, Nagarsenker MS. Self-nanoemulsifying drug delivery systems: formulation insights, applications and challenges. [Drug-delivery review].
29. Microemulsions as drug delivery systems to improve the solubility and the bioavailability of poorly water-soluble drugs. *Expert Opin Drug Deliv*. 2010.
30. Microemulsion utility in pharmaceuticals: implications for multi-drug delivery. [Pharmaceutical microemulsion review]. 2017.

HOW TO CITE: Prakarsh Giri, Dhananjay Rai, Dengue Fever Management: Pathophysiology, Therapeutic Challenges, Potential of *Carica Papaya* Leaf, and Advanced Drug Delivery Systems, *Int. J. of Pharm. Sci.*, 2026, Vol 4, Issue 10, 3284-3304. <https://doi.org/10.5281/zenodo.23572759>

